- Home
- MAMO vs BDSX Comparison
MAMO vs BDSX Comparison
Compare MAMO & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAMO
- BDSX
- Stock Information
- Founded
- MAMO 2008
- BDSX 2005
- Country
- MAMO United States
- BDSX United States
- Employees
- MAMO N/A
- BDSX N/A
- Industry
- MAMO
- BDSX Precision Instruments
- Sector
- MAMO
- BDSX Health Care
- Exchange
- MAMO NYSE
- BDSX Nasdaq
- Market Cap
- MAMO 98.1M
- BDSX 115.4M
- IPO Year
- MAMO 2024
- BDSX 2020
- Fundamental
- Price
- MAMO $2.28
- BDSX $0.35
- Analyst Decision
- MAMO
- BDSX Strong Buy
- Analyst Count
- MAMO 0
- BDSX 4
- Target Price
- MAMO N/A
- BDSX $2.83
- AVG Volume (30 Days)
- MAMO 15.1K
- BDSX 523.2K
- Earning Date
- MAMO 05-13-2025
- BDSX 05-13-2025
- Dividend Yield
- MAMO N/A
- BDSX N/A
- EPS Growth
- MAMO N/A
- BDSX N/A
- EPS
- MAMO 0.08
- BDSX N/A
- Revenue
- MAMO $111,209,142.00
- BDSX $71,323,000.00
- Revenue This Year
- MAMO N/A
- BDSX $32.90
- Revenue Next Year
- MAMO N/A
- BDSX $24.65
- P/E Ratio
- MAMO $29.64
- BDSX N/A
- Revenue Growth
- MAMO N/A
- BDSX 45.30
- 52 Week Low
- MAMO $2.16
- BDSX $0.45
- 52 Week High
- MAMO $4.66
- BDSX $2.04
- Technical
- Relative Strength Index (RSI)
- MAMO N/A
- BDSX 26.08
- Support Level
- MAMO N/A
- BDSX $0.34
- Resistance Level
- MAMO N/A
- BDSX $0.58
- Average True Range (ATR)
- MAMO 0.00
- BDSX 0.06
- MACD
- MAMO 0.00
- BDSX -0.01
- Stochastic Oscillator
- MAMO 0.00
- BDSX 4.62
About MAMO MASSIMO GROUP
Massimo Group is engaged in the mid-tier band the (Mid-Tier Band) of the Powersports Vehicles and Boats Industry. It manufacture, import and distribute a diversified portfolio of products divided into two main lines: a motor sports brand consisting of utility terrain vehicles (UTVs), all-terrain vehicles (ATVs), motorcycles, scooters, golf carts, and a juvenile line from go karts to balance bikes; and a motor boat line consisting of pontoon and tritoon boats (Pontoon Boats).
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.